Our Products

Product details Products Home
Tigicon

Tigicon

Fenofibrate

Fenofibrate is a fibric acid derivative. Fenofibrate is rapidly hydrolysed after oral ingestion into its pharmacologically active form fenofibric acid. Fenofibrate reduces total cholesterol, LDL cholesterol, apoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, Fenofibrate increases high density lipoprotein (HDL) and apo Al and apo All. The effects of Fenofibrats have seen in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor a (PPARa). Fenofibrate also reduces serum uric acid levels in hyperuremic patients by increasing the urinary excretion of uric acid.

Product Details

Presentation

Tigicon Capsule: Each capsule contains Fenofibrate BP 200 mg.

Pharmacology

Fenofibrate is a fibric acid derivative. Fenofibrate is rapidly hydrolysed after oral ingestion into its pharmacologically active form fenofibric acid. Fenofibrate reduces total cholesterol, LDL cholesterol, apoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, Fenofibrate increases high density lipoprotein (HDL) and apo Al and apo All. The effects of Fenofibrats have seen in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor a (PPARa). Fenofibrate also reduces serum uric acid levels in hyperuremic patients by increasing the urinary excretion of uric acid.

Indication

Tigicon is indicated for treatment of hyperlipidemia of Type IIa, IIb, III, IV and V in patients who have not responded adequately to diet & other appropriate measures.

Dosage & Administration

The dose is one capsule per day. Fenofibrate capsule should be taken after meal. Renal insufficiency: The dosage of Fenofibrate should be minimized in patients who have severe renal impairment.

Contraindications

Patients with liver disease or gallstone, renal impairment & hypersensitivity to Fenofibrate.

Warning & Precautions

Special care should be needed In patients with renal disease. Discontinuation of the drug is necessary if creatinine kinase concentration increases significantly.

Side effects

Nausea, anorexia, gastric pain, pruritus, urticaria, headache, dizziness, vertigo, fatigue.

Drug interaction

Fenofibrate potentiates the action of oral anticoagulants. In patients receiving oral anticoagulant therapy the dose should be reduced by one third on starting Fanofibrates. Fenofibrates should not be used in combination with perhexiline maleate or with monoamine oxidase inhibitors.

Use in special groups

Use in ediatrics: Fenofibrate has not been investigated in adequate and well controlled trials in pediatric patients.
Use in pregnancy & nursing mothers: Fenofibrate is contraindicated during pregnancy & nursing mothers.

Packing

Tigicon Capsule: Each box contains 30's capsules in blister pack.

Other Products from
Lipid Lowering Agent
 
Pitavastatin
Rosuvastatin
Atorvastatin
Fenofibrate

© 2017. Aristopharma Ltd. All rights reserved.
Site by DIGITA iNTERACTIVE

HOME | PRODUCTS | FACILITIES | GLOBAL PRESENCE | NEWS | ABOUT US | CONTACT | CAREER

Webmail
Bookmark and Share